Dehydroepiandrosterone in systemic lupus erythematosus.
Dehydroepiandrosterone (DHEA) is a weak androgen that exerts pleomorphic effects on the immune system. The hormone has no known receptor, and consequently, its mechanism of action on immunocompetent cells remains poorly understood. Interestingly, serum levels of DHEA are decreased in patients with inflammatory diseases including lupus, and these levels seem to correlate inversely with disease activity. Following encouraging studies demonstrating beneficial effects of DHEA supplementation in murine lupus models, several clinical studies have tested the effect of DHEA in lupus patients. DHEA treatment could improve overall quality-of-life assessment measures and glucocorticoid requirements in some lupus patients with mild to moderate disease; however, DHEA's effect on disease activity in lupus patients remains controversial. Long-term safety studies are required in light of the reported effect of DHEA supplementation in lowering high-density lipoprotein cholesterol in lupus patients.
Sawalha
Amr H
AH
amr-sawalha@omrf.ouhsc.edu
Kovats
Susan
S
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000328:Adult; D000818:Animals; D016207:Cytokines / Q000276:immunology; D003687:Dehydroepiandrosterone / Q000097:blood / Q000276:immunology* / Q000494:pharmacology; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology*; D051379:Mice
D000276:Adjuvants, Immunologic; D016207:Cytokines; D003687:Dehydroepiandrosterone